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Abstract 
Rationale: The evaluation of early treatment response is critical for patient prognosis and treatment planning. 
When the current methods rely on invasive protocols that evaluate the expression of DNA damage markers 
on patient biopsy samples, we aim to evaluate a non-invasive PET imaging approach to monitor the early 
expression of the phosphorylated histone γH2AX in the context of pancreatic cancer targeted radionuclide 
therapy. Pancreatic ductal adenocarcinoma has a poor patient prognosis due to the absence of curative 
treatment for patients with advanced disease. There is therefore a critical need for the fast clinical translation 
of new therapeutic options. In line with these observations, our group has been focusing on the development 
of radiotheranostic agents based on a fully human monoclonal antibody (5B1) with exceptional affinity for 
CA19.9, an antigen overexpressed in PDAC. Two on-going clinical trials resulted from these efforts, one with 
89Zr (diagnosis) and one with 177Lu (β-particle therapy). More recently, we successfully developed and 
evaluated in PDAC mouse models a targeted α-therapy strategy with high clinical translation potential. We aim 
to expedite the clinical translation of the developed radioimmunotherapy approaches by investigating the early 
therapeutic response and effect of radiation therapy in a PDAC mouse model via PET imaging. 
Methods: Mice bearing BxPC3 tumor xenografts were treated with α- and β-particle pretargeted 
radioimmunotherapy (PRIT), external beam radiotherapy (EBRT), or sham-treated (vehicle). The 
phosphorylated histone γH2AX produced as a response to DNA double strand breaks was quantified with the 
PET radiotracer, [89Zr]Zr-DFO-anti-γH2AX-TAT.  
Results: PET imaging studies in BxPC3 PDAC mouse models demonstrated increased uptake of 
[89Zr]Zr-DFO-anti-γH2AX-TAT (6.29 ± 0.15 %IA/g) following β-PRIT in BxPC3 PDAC xenografts as 
compared to the saline control group (4.58 ± 0.76 %IA/g) and EBRT control group (5.93 ± 0.76 %IA/g). 
Similarly, significantly higher uptake of [89Zr]Zr-DFO-anti-γH2AX-TAT was observed in tumors of the 
225Ac-PRIT and EBRT (10 Gy) cohorts (7.37 ± 1.23 and 6.80 ± 1.24 %IA/g, respectively) compared to the 
negative control cohort (5.08 ± 0.95 %IA/g). Ex vivo γH2AX immunohistochemistry and immunofluorescence 
analysis correlated with in vivo 89Zr-anti-γH2AX PET/CT imaging with increased γH2AX positive cell and 
γH2AX foci per cell in the treated cohorts. When α-PRIT resulted in prolonged overall survival of treated 
animals (107.5 days) as compared to β-PRIT (73.0 days), no evidence of difference in 
[89Zr]Zr-DFO-anti-γH2AX-TAT uptake at the tumor site was observed, highlighting that DNA damage is not 
the sole radiobiology paradigm and that off-targeted (bystander) effects should be considered. 
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Conclusions: PET imaging studies with [89Zr]Zr-DFO-anti-γH2AX-TAT following α- and β-particle PRIT in a 
BxPC3 PDAC subcutaneous xenograft mouse model allowed the monitoring of tumor radiobiological response 
to treatment. 
Key words: Radioimmunotherapy, DNA damage, γH2AX, PET, pancreatic cancer 
Introduction 
With a 5-year survival rate in the US of 9%, 
pancreatic ductal adenocarcinoma (PDAC) is a 
uniformly lethal disease [1,2]. This dire prognosis is 
partly due to a lack of screening and diagnostic tools, 
but also limited therapeutic options [1]. To solve these 
issues, our group has been developing clinically 
translatable diagnostic and therapeutic approaches 
based on antibody radioconjugates for the positron 
emission tomography (PET) imaging and 
radioimmunotherapy (RIT) of PDAC [3–6].  
The Sialyl-Lewisa (sLea), also known as CA19.9 
antigen, is one of the most widely studied pancreatic 
cancer biomarkers as patients’ serum levels correlate 
with cancer stage, prognosis or treatment response [7–
9]. The fully human 5B1 antibody, generated from 
blood lymphocytes from a patient immunized with a 
sLea – KLH vaccine, demonstrates exceptional affinity 
and high specificity for an extracellular epitope of 
CA19.9 [10,11]. In 2016, the clinical potential of 
CA19.9 as a therapeutic target was investigated in 
patients with pancreatic cancers or CA19.9-positive 
malignancies (NCT02672917) via the weekly 
intravenous administration of 5B1 (MVT-5873). This 
antibody was also evaluated as a platform for the 
specific delivery of radioisotopes to PDAC tumor 
sites. Two on-going clinical trials with 5B1-based 
radioimmunoconjugates resulted from these studies: 
one in which the antibody is labeled with 89Zr for PET 
imaging (NCT02687230) and a second in which the 
antibody is labeled with 177Lu for β-RIT 
(NCT03118349). More recently, our group evaluated 
the potential of 225Ac labeled 5B1-conjugates for α-RIT 
in PDAC mouse models [6]. During these preclinical 
investigations, a pretargeted administration method 
relying on the inverse electron demand Diels-Alder 
reaction [4,5,12–15] was compared to conventional 
RIT. Pretargeted RIT (PRIT) allowed the delivery of 
α-radioactive payloads to PDAC tumor sites while 
reducing the mean absorbed dose to healthy tissues, 
enabling prolonged survival and reduced 
haematotoxicity in subcutaneous and orthotopic 
models of PDAC as compared to conventional RIT [6]. 
The clinical translation of α-based PRIT for PDAC 
would complement the two on-going 5B1-based 
clinical trials for the diagnosis (89Zr) and β-therapy 
(177Lu) of PDAC and has the potential to extend the 
population of patients eligible for CA19.9-targeted 
radiotherapy to include those with residual metastatic 
lesions as well as patients that develop resistance to 
β-therapy. 
To expedite the clinical translation of new 
targeted radiotherapies (for small molecule, peptide 
and antibody-based systems), we aim to validate a 
PET imaging platform for the evaluation of early 
treatment response. Conventional methods to assess 
therapeutic response rely on the monitoring of tumor 
dimensions through anatomic imaging techniques 
such as X-ray, CT or MRI [16,17]. The visualization 
and quantification of cellular or biochemical 
responses to treatment through molecular imaging 
techniques offer the incredible opportunity for early 
treatment response monitoring when anatomical 
changes cannot be measured yet [18]. The monitoring 
of therapeutic response after radiotherapy can be 
gauged by the quantification of DNA damage [19]. 
DNA double-strand breaks (DSBs) are the most severe 
forms of DNA damage and one of the main 
mechanisms through which radiotherapy leads to 
apoptosis [20]. As DNA DSBs are not present in large 
numbers, they do not represent an ideal target for 
molecular imaging. An alternative strategy lays in the 
targeting of DNA damage response proteins such as 
phosphorylated γH2AX which is present exclusively 
in the cell nucleus as foci containing thousands of 
copies around individual DNA DSBs [21–23]. In a 
clinical setting, quantification of γH2AX foci is 
performed by the immunohistochemistry evaluation 
of biopsied samples [24]. However, this method is 
invasive, associated with risks (e.g. bleeding, 
infection), not adequate for a disseminated disease 
and can be biased by tumor heterogeneity. At the 
preclinical stage, non-invasive SPECT (111In) and PET 
(89Zr) imaging techniques were developed to quantify 
γH2AX expression levels in vivo. Cornelissen et al. 
functionalized an anti-γH2AX antibody that binds 
both human and mouse γH2AX with a cell 
penetrating peptide (TAT) that contains a nuclear 
localization sequence and a chelator (DFO or DTPA) 
for further radiolabeling with 89Zr or 111In [25–27]. The 
uptake of the SPECT imaging agent, [111In]In-anti- 
γH2AX-TAT, and the PET imaging agent, 
[89Zr]Zr-DFO-anti-γH2AX-TAT, was shown to be 
linearly dependent of the number of γH2AX foci per 
cell as well as the absorbed dose of radiation 
deposited at the tumor site by external beam radiation 
[25,27]. The ability of [89Zr]Zr-DFO-anti-γH2AX-TAT 
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to monitor early therapeutic response following 
chemotherapy was investigated in a PDAC mouse 
model [28]. It was demonstrated that [89Zr]Zr-DFO- 
anti-γH2AX-TAT allows early indication of therapy 
response when the clinical standard, [18F]F-FDG, did 
not provide any indication after initiation nor 
completion of the treatment [28]. Recently, 
[111In]In-anti-γH2AX-TAT allowed the non-invasive 
visualization of DNA damage following molecular 
targeted radionuclide therapy with [177Lu]Lu-DOTA- 
TATE in a preclinical mouse model of pancreatic 
neuroendocrine cancer [29]. A dual isotope SPECT 
imaging strategy, allowing the simultaneous imaging 
of 177Lu and 111In, highlighted the correlation of the 
177Lu dose heterogeneity to the uptake of 
[111In]In-anti-γH2AX-TAT. This study opened the 
path toward the evaluation of the DNA damage 
imaging approach for a larger range of targeted 
radionuclide therapy approaches including α- and 
β-RIT.  
In this study, we investigated the ability of 
[89Zr]Zr-DFO-anti-γH2AX-TAT to monitor the 
activation of DNA damage response following α- and 
β-PRIT in a subcutaneous PDAC mouse model. We 
hypothesized that the in vivo quantification of γH2AX 
via PET imaging will provide an early readout of 
α-/β-PRIT efficacy. Such approach to early 
radiotherapy response is a critical tool for the clinical 
translation of new radiotherapy approaches, as it 
would ultimately expedite the translation evaluation 
time. Furthermore, this technology will be applicable 
to numerous radiotherapeutic delivery platforms, 
including small molecules, peptides, antibodies and 
nanoparticles, and will help streamline their 
development and translation. 
Materials and Methods 
Radiochemistry 
The synthesis of DOTA-PEG7-Tz was performed 
using the previously published synthetic pathway [5]. 
The conjugation of TCO-NHS to 5B1 was performed 
according to previously published methods [5,6]. 
177Lu was obtained from either ITG (Germany) or the 
University of Missouri Research Reactor through the 
United States Department of Energy Office of Science. 
225Ac was supplied by the United States Department 
of Energy Office of Science by the Isotope Program in 
the Office of Nuclear Physics. 177Lu- and 
225Ac-radiolabeling was performed according to 
protocols previously published by our group [5,30]. 
225Ac-radiopharmaceuticals for in vitro and in vivo 
evaluation were prepared and used at least 4 h after 
the purification of the radiotracers to allow actinium 
to reach a pseudo-equilibrium state and have an 
accurate reading of the activity used/injected. 225Ac 
samples from in vitro and in vivo assays were 
measured on a gamma counter once secular 
equilibrium was reached (> 24 hours). 
The anti-γH2AX immunoconjugate for 
molecular imaging of DNA damage response was 
prepared following the published protocol [27]. 
Succinctly, the free lysine residues of a mouse 
monoclonal anti-γH2AX antibody (Merck, clone 
JBW-301) were activated with an N-hydroxysuc-
cinimidyl ester. The activated antibody was then 
conjugated to a TAT (GRKKRRQRRRPPQGYG) 
peptide, a cell penetrating peptide with a 
non-canonical nuclear localization sequence [25]. The 
resulting immunoconjugate was then reacted with 
pSCN-Bn-deferoxamine (DFO) for further 
radiolabeling with 89Zr. 89Zr was produced through 
proton-beam bombardment of yttrium foil and 
isolated in high purity as 89Zr-oxalate at Memorial 
Sloan Kettering Cancer Center according to a 
previously published procedure [31]. 89Zr-oxalate (10 
MBq) was neutralized to pH 6.9–7.2 with 1 M Na2CO3. 
The DFO-anti-γH2AX-TAT in PBS buffer (pH 7.4) was 
added (100 μg), and the reaction was incubated at 
room temperature for 1 h with a gentle shaking (400 
rpm).  
Purity and radiolabeling efficacies were 
quantified through instant thin-later chromatography 
(iTLC) with a 50 mM ethylenediaminetetraacetic acid 
(pH 5, 177Lu and 225Ac), or a 0.1 M sodium citrate (pH 
5.0, 89Zr) mobile phase. Radiochemical purity was 
routinely >99%. 
Cell lines and xenograft models 
CA19.9-positive BxPC3 cells were grown in 
RPMI medium modified to contain 4.5 g/L sodium 
bicarbonate and supplemented with 10 % (vol/vol) 
heat-inactivated FCS, 100 IU penicillin, 100 μg/mL 
streptomycin, 10 mM HEPES, and 10 cc/L 
nonessential amino acids. All animals were treated 
according to the guidelines approved by the Research 
Animal Resource Center and Institutional Animal 
Care and Use Committee at Memorial Sloan Kettering 
Cancer Center. Female athymic homozygous nude 
mice (strain: Crl:NU(NCr)-Foxn1nu, Charles River 
Laboratories, Wilmington, MA, aged 6-8 weeks) were 
xenografted subcutaneously with 5×106 BxPC3 cells 
suspended in 150 μL of a 1:1 Matrigel (Becton 
Dickson, Bedford, MA) and cell culture medium 
mixture. 
Cell viability 
Cell viability 48 hours after [177Lu]Lu-DOTA-5B1 
and [225Ac]Ac-DOTA-5B1 treatment was evaluated. 
BxPC3 cells (2x104 cells) were seeded in 96 well plates 
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and incubated for 4 h. [177Lu]Lu-DOTA-5B1 (220 
MBq/mL to 0.55 kBq/mL) and [225Ac]Ac-DOTA-5B1 
(2.97 MBq/mL to 7.4 Bq/mL) were added to the cells 
for 48h. Each concentration was run as 
quadruplicates. After 48 hours of treatment, a 
tetrazolium salt MTT (10 μL, 50 μg/mL) was added 
and incubated at 37°C for 1 hour. After that, a 0.04 M 
HCl solution in 10% Triton-x isopropanol (100 μL) 
was added. Absorption at 570 nm was detected on a 
SpectraMax M5 (Molecular Devices) plate reader. This 
experiment was performed twice; ED50 values are 
presented as the mean value of these two replicates.  
Clonogenic survival 
BxPC3 cells (1,000-3,000) were plated in 6-well 
plates in growth media and incubated for 4 h at 37°C 
in 5% CO2. Cells were then treated with 
[177Lu]Lu-DOTA-5B1 (0.22 to 1.51 MBq/mL), 
[225Ac]Ac-DOTA-5B1 (0.08 to 5.01 kBq/mL), or sham 
treated (cell media + radiopharmaceutical vehicle). 
After 48 h, the treatment-containing supernatant 
media was removed and cells were washed with PBS. 
Cells were then incubated with 2.5 mL of growth 
media for 12 days at 37°C in 5% CO2. After 12 days, 
the media was removed and cells were gently washed 
with PBS. Cells were then fixed and stained with 3 mL 
of a mixture of 6% glutaraldehyde and 0.5% crystal 
violet. Colonies of at least 50 cells (~ 0.5 mm) were 
counted manually. The plating efficiency, defined as 
the ratio of the number of colonies formed by the 
number of cells seeded, was determined using the 
sham treated cells. The surviving fraction is defined as 
the number of colonies formed after treatment 
divided by the number of cells seeded multiplied by 
the platting efficiency. 
CA19.9 pretargeted radioimmunotherapy 
Tumor volumes were monitored with a Peira 
TM900 imaging device (Peira, Belgium). Four weeks 
after PDAC cells implantation, mice were randomized 
into cohorts (n = 8) according to their tumor volume. 
The mean tumor volume of each cohort was 
approximately equal to 150 mm3. The study was then 
blinded for the technical person responsible of tumor 
measurements so that the volume acquired were not 
biased. One day after randomization, mice receiving 
PRIT were injected with 5B1-TCO (200 μg, 1 nmol; in 
200 μL of PBS). Seventy-two hours later, mice were 
injected with the appropriate radioactive payload: 
either [177Lu]Lu-DOTA-PEG7-Tz (18.5 MBq, 0.4 nmol) 
or [225Ac]Ac-DOTA-PEG7-Tz (37 kBq, 0.4 nmol) for 
PRIT. The control cohorts were injected with either 
vehicle (0.9 % sterile saline) or 5B1-TCO alone). 
Tumor volume and body weight were measured 
twice a week until 120 days or until mice reached the 
set volume endpoint (> 2000 mm3). Mice were 
monitored for outward signs of toxicity, including 
lethargy, loss of appetite, or disseminated 
intravascular coagulation.  
In vivo γH2AX PET imaging 
Four weeks post-subcutaneous PDAC cells 
implantation, mice with an average tumor volume of 
about 120 mm3 were randomized into cohorts 
(n=5/cohort) and used for PET/CT imaging studies. 
Three days post-administration of 177Lu-/225Ac-PRIT 
(18.5 MBq/0.037 MBq, 0.4 nmol), 
[89Zr]Zr-DFO-anti-γH2AX-TAT (0.5 MBq, 5.0 μg) was 
administered intravenously. As a positive control, 
γH2AX was induced in mice by X-ray irradiation of 
the tumor (X-RAD 320). One hour before the injection 
of the PET imaging probe, positive control mice were 
irradiated (10 Gy) at a dose rate of 1.2 Gy/min. As 
negative control, mice were mock-treated (0 Gy). 
PET/CT imaging was performed on an Inveon 
PET/CT scanner (Siemens) up to 4 days post-injection 
of [89Zr]Zr-DFO-anti-γH2AX-TAT. Images were 
processed using the Inveon Research Workplace 
software package. Volume of interests (VOIs) analysis 
was performed using 3D Slicer. VOIs were drawn 
around the major organs of interest and the tumor. CT 
scans were used for volume measurements (cm3) 
when PET scans were used for quantification of the 
activity in the organ of interest. VOIs are presented as 
percent injected activity per cm3 (%IA/cm3). After 
imaging, mice were euthanized; organs were 
collected, weighted and counted on an automatic 
gamma counter. Results are presented as the injected 
activity per gram (%IA/g). 
Ex vivo γH2AX staining 
Separate mice cohorts (n=3/cohort) were treated 
as previously described. However, three days 
post-injection of the radionuclide therapy, mice were 
euthanized and their tumors were collected for 
γH2AX staining. Immunohistochemistry and 
immunofluorescence were carried out on 
formalin-fixed, paraffin-embedded 10-μm-thick 
tumor sections. Sections were submitted to MSKCC 
Molecular Cytology Core Facility for γH2AX as well 
as hematoxylin and eosin staining. Slides were 
scanned using a Pannoramic Flash 250 slide scanner 
from 3DHistech (Budapest, Hungary) - Zeiss 
20x/0.8NA objective. Immunohistochemistry was 
used for the determination of γH2AX positive cells 
when immunofluorescence was used for the detection 
of γH2AX foci per cell. Immunohistochemistry cell 
positive analysis was performed in random tumor 
areas (n = 8/sample) using the open source software 
QuPath [32]. The total number of cells was 
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determined using the hematoxylin staining whereas 
the DAB staining was used to quantify the percentage 
of positive cells. Immunofluorescence analysis was 
performed using the open source image processing 
package Fiji [33]. The mean FITC fluorescence 
intensity was normalized to the DAPI fluorescent 
signal and the number of foci/cell were counted in 
random tumor areas (n =6/sample). 
Statistical analyses 
All data are represented as mean value ± 
standard deviation (n = 5-8, unless otherwise noted). 
The sample sizes were selected taking into account 
both statistical consideration and the exigencies of 
funding. For the PET imaging and biodistribution 
studies, a minimum of 4 animals were required to 
obtain a statistical power > 0.8 (bilateral test, δ = 1.3, σ 
= 0.6, α = 0.05). For the therapy studies, a minimum of 
8 animals were required to obtain a statistical power > 
0.8 (bilateral test, δ = 25, σ = 17, α = 0.05). The 
significance analyses were performed using Prism 8.3, 
employing one-way ANOVA followed by a Dunnett’s 
multiple comparisons test and log rank Mantel-Cox 
test as detailed in figure legends. A P value of <0.05 
was considered significant. 
Results 
Exposure to α- and β-RIT results in differential 
viability in BxPC3 PDAC cell line 
Viability of the BxPC3 PDAC cell line after 
treatment with [225Ac]Ac-DOTA-5B1 and 
[177Lu]Lu-DOTA-5B1 was evaluated through an MTT 
assay. Reduced viability of the BxPC3 cell line was 
observed after a 48-hour incubation with 
[225Ac]Ac-DOTA-5B1 at activity concentrations 
greater than 0.002 MBq/mL (Figure 1A). The mean 
ED50 value of two replicate experiments was 
calculated to 0.26 ± 0.17 MBq/mL. After a 48-hour 
incubation with [177Lu]Lu-DOTA-5B1, a reduced cell 
viability was observed as well. However, much higher 
activity concentrations (> 8 MBq/mL) were required 
(Figure 1A, Figure S1). The ED50 value after 
[177Lu]Lu-DOTA-5B1 treatment was calculated to 122 
± 74 MBq/mL. The ratio of cytotoxic effects between 
the α- and β-RIT treatments was calculated to be 483 ± 
39.  
As the method of choice to determine cell 
reproductive death after ionizing radiation, 
clonogenic assays were performed and confirmed the 
higher potency of [225Ac]Ac-DOTA-5B1 as compared 
to [177Lu]Lu-DOTA-5B1 (Figure 1B-C). Only 0.2 
kBq/mL of [225Ac]Ac-DOTA-5B1 were required to 
achieve a surviving fraction of 0.5 (SF0.5), when 560 
kBq/mL were needed to result in similar effects with 
[177Lu]Lu-DOTA-5B1. The ratio of cytotoxic effects 
between the α- and β-RIT treatments was here 
calculated to 2,800. 
Based on these two cytotoxic experiments and 
the different physical properties of the radionuclides 
used, the relative biological effectiveness between our 
α- and β-RIT was determined (see SI for calculation 
details). In the conditions of our MTT assay, 
[225Ac]Ac-DOTA-5B1 was 3.7 ± 0.3 times more 
cytotoxic than [177Lu]Lu-DOTA-5B1. Comparatively, a 
21-fold ratio was found between [225Ac]Ac-DOTA-5B1 
and [177Lu]Lu-DOTA-5B1 in the settings of our 
clonogenic experiment (SF0.5). The variability of the 
relative biological effectiveness between α- and β-RIT 
calculated for these two experiments highlights the 
importance of the selected survival endpoint.  
α-PRIT results in prolonged survival as 
compared to β-PRIT without sign of toxicity 
For α- and β-RIT therapy studies, the 
pretargeting administration method was chosen due 
to its demonstrated potency and its ability to reduce 
absorbed dose to healthy tissues and thereof toxicities 
(Figure 1D). Based on the aforementioned in vitro 
assays and our previously published PRIT studies 
with 177Lu and 225Ac, the injected activities for 
[177Lu]Lu-DOTA-PEG7-Tz and [225Ac]Ac-DOTA- 
PEG7-Tz were set to 18.5 MBq and 0.037 MBq, 
respectively [5,6]. With these injected activities, a 
factor of 500, in the same range as the ratio observed 
for equitoxic effects in our MTT assay, applies 
between the 177Lu- and 225Ac-PRIT. For both PRIT 
approaches, the injected mass of 5B1-TCO and 
Tz-radioligand were equal. Our group previously 
reported similar pharmacokinetics and tumoral 
uptake between the α- and β-PRIT strategies [5,6]. The 
absorbed dose delivered to the tumor was estimated 
using mouse dosimetry extrapolated from 
biodistribution studies previously performed with 
177Lu-/225Ac-PRIT [5,6]. The tumor absorbed dose was 
evaluated to 102 Gy for 177Lu-PRIT and 75 Gy for 
225Ac-PRIT. The accepted threshold for a meaningful 
response with EBRT in solid tumors being 100 Gy, a 
significant therapeutic effect was expected for both 
PRIT treatment group. Control groups were injected 
with either saline (vehicle) or 5B1-TCO alone. 
Survival analysis suggested therapeutic effects in 
both PRIT cohorts compared with control groups (P 
values <0.01) (Figure 1E). Median survival for the 
group treated with 177Lu-PRIT (73.0 days) and 
225Ac-PRIT (107.5 days) highlighted the superior 
therapeutic potential of α-PRIT in our setting (P value 
< 0.05). Mean tumor volume are provided in 
supporting information and correlated with the 
survival results (Figure S2). Even though, the tumor 
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absorbed dose was 25 % less in the α-PRIT cohort, the 
higher therapeutic efficacy of this treatment as 
compared to β-PRIT suggests that the relative 
biological effectiveness of 5 recommended by the US 
Department of Energy for effective dose calculations 
with α-particle emitters might be under-estimated. 
The body weight progression for 225Ac-PRIT showed a 
transient deviation from control groups and the 
177Lu-PRIT cohort from day 3 to day 21 after the 
administration of the systemic radiotherapy (Figure 
S2). Nevertheless, no weight loss exceeded the 20% 
threshold that would have required the early 
euthanasia of the animal. No other sign of gross acute 
toxicity was observed. All the mice were sacrificed 
when their tumor reached the set endpoint of > 2000 
mm3 or at 120 days. 
 
 
Figure 1. In vitro and in vivo evidence of the higher cytotoxic potential of α-RIT compared to β-RIT A. Viability of BxPC3 PDAC cells after a 48 hours incubation with various 
activity concentration of [177Lu]Lu-DOTA-5B1 and [225Ac]Ac-DOTA-5B1 (n=4 per concentration). B. Clonogenic survival of BxPC3 cells exposed to [177Lu]Lu-DOTA-5B1 (n=6 
per concentration). C. Clonogenic survival of BxPC3 cells exposed to [225Ac]Ac-DOTA-5B1 (n=6 per concentration). D. Schematic representation of the PRIT dosing schedule. 
E. Percent survival as function of time after PRIT injection. Mice were sacrificed when tumor >2000 mm3. Survival data reflect the progression of primary subcutaneous tumors 
(n=8 per cohort). Values are represented as means, and error bars represent standard deviations. 
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Exposure to β-PRIT in BxPC3 PDAC 
xenografts induces increased uptake of 
[89Zr]Zr-DFO-anti-γH2AX-TAT as compared 
to controls 
In an attempt to measure in vivo the response to 
177Lu-PRIT, [89Zr]Zr-DFO-anti-γH2AX-TAT was used 
to visualize DNA damage via PET imaging. Mice 
were treated with 177Lu-PRIT (18.5 MBq) 72 hours 
prior the injection of the PET anti-γH2AX tracer to 
allow sufficient dose deposition and induction of 
γH2AX at the tumor site (Figure 2A) [34]. Positive and 
negative control cohorts were treated according to 
established protocols (Figure 2A). PET images were 
recorded at multiple time points after the injection of 
the PET tracer to define the best time point for the 
visualization of DNA damage after PRIT. 
Representative transverse images are shown in Figure 
2B, coronal sections and maximum intensity 
projections are shown in the supporting information 
(Figure S3). VOI analyses of tumors were performed at 
the different time points (Figure 2C, Figure S4A). At the 
4 days imaging time point, a statistically significant (P 
value < 0.01) increased uptake of [89Zr]Zr-DFO- 
anti-γH2AX-TAT was observed in the 177Lu-PRIT 
cohort as compared to the negative control. An 
increasing uptake trend was also observed with the 
positive control (10 Gy) cohort (P < 0.05). Analysis of 
the area under the curve revealed a statistically 
significant increased accumulation of [89Zr]Zr-DFO- 
anti-γH2AX-TAT over the 4 day imaging period in 
both 10 Gy and 177Lu-PRIT cohorts (Figure 2D). In 
every cohort, the uptake of [89Zr]Zr-DFO-anti- 
γH2AX-TAT in the tumor increases up to 24 hours 
post-injection of the 89Zr-PET radiotracer before 
reaching a plateau. Consequently, the 24 hours 
imaging time point will as of now be used in this 
study for the in vivo evaluation of DNA damage with 
[89Zr]Zr-DFO-anti-γH2AX-TAT. After the final image 
acquisition, mice were sacrificed and organs of 
interest were counted on a γ-counter to confirm the 
PET imaging results. The biodistribution confirmed 
the significantly higher accumulation of 
[89Zr]Zr-DFO-anti-γH2AX-TAT in irradiated tumors 
(Figure 2E). Cohorts irradiated with 10 Gy of external 
beam radiation or 177Lu-PRIT showed increased 
retention of the 89Zr-PET anti-γH2AX tracer with 
uptake of 5.93 ± 0.76 and 6.29 ± 0.15 %IA/g, 
respectively. The uptake in our negative control 
cohort was significantly lower with 4.58 ± 0.76 %IA/g. 
The full biodistribution profile of [89Zr]Zr-DFO-anti- 
γH2AX-TAT (Figure S4C) matches the expectations for 
a full-length IgG radioimmunoconjugates with an 
hepatobiliary clearance and prolonged half-life in the 
blood and vascularized organs. We observed a 
significantly higher accumulation of [89Zr]Zr-DFO- 
anti-γH2AX-TAT in the blood, well-perfused organs 
(e.g. heart, lungs) and in the spleen of irradiated 
animals (Figure S4B-C). In the case of the 177Lu-PRIT 
cohort, the uptake of [177Lu]Lu-DOTA-PEG7-Tz in the 
blood 72 hours post-injection is 1.51 ± 0.21 %IA/g and 
the mean absorbed dose was calculated to be 48.8 
cGy/MBq, therefore approximately 9.0 Gy was 
delivered to the blood [5]. Even though no 
hematotoxicity was reported in our previous studies 
with 177Lu-PRIT, such a dose could result in the 
generation of off-target toxicities and therefore 
elevated γH2AX level in the blood. In the case of the 
10 Gy external beam radiation cohort, the mice were 
positioned on the outside X-ray field and only their 
lower right side were exposed to the radiation. 
Therefore, according to the dose delivered and their 
position we didn’t expected any significant toxicity to 
the blood. The radiation exposure is consequently not 
expected to be the source of the increased uptake of 
89Zr-PET anti-γH2AX tracer.  
α-PRIT results in an increased 
[89Zr]Zr-DFO-anti-γH2AX-TAT tumoral 
uptake that correlates with the prolonged 
survival of the animals as compared to β-PRIT 
Following the protocol established with 
177Lu-PRIT, PET imaging of DNA damage following 
225Ac-PRIT (37 kBq) was undertaken. Representative 
transverse images of [89Zr]Zr-DFO-anti-γH2AX-TAT 
uptake at the tumor site 24 hours post-intravenous 
injection of the PET radiotracer are reported in Figure 
3A. Coronal sections and maximum intensity 
projections are provided in supporting information 
(Figure S5A). Quantitative VOI analysis of the 
89Zr-PET signal revealed a statistically significant (P < 
0.05) increase of the tumor [89Zr]Zr-DFO-anti- 
γH2AX-TAT uptake in the 225Ac-PRIT cohort (Figure 
3B). VOI analysis was compared to the results 
determined through ex vivo gamma-counting 
post-animal sacrifice (Figure S6). The uptake of the 
89Zr-PET DNA damage radiotracer in the 225Ac-PRIT 
and positive control (10 Gy) cohorts was 7.37 ± 1.23 
and 6.80 ± 1.24 %IA/g, respectively, when the 
negative control cohort uptake was 5.08 ± 0.95 %IA/g 
(Figure 3C, Figure S5B). These results were in perfect 
agreement with the PET VOI values. 
Comparing the 225Ac-PRIT and 177Lu-PRIT 
imaging cohorts is rendered difficult due to 
confounding factors that include different animal 
cohorts, PET radiotracer synthesis, or PET imaging 
endpoint (4 days post-radiotracer administration for 
177Lu-PRIT and 24 hours for 225Ac-PRIT). However, 
there is no evidence of difference between the two 
different negative and positive control cohorts. No 
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statistically significant differences can be observed 
between the 225Ac-PRIT and 177Lu-PRIT cohorts with 
our DNA damage PET imaging tracer (Figure 3D), 
even though 225Ac-PRIT resulted in prolonged 
survival of the treated animal as compared to 
177Lu-PRIT. This study seems to indicate that DNA 
damage is not the only apoptotic pathway involved in 
the therapeutic efficacy of our PRIT approaches.  
 
 
Figure 2. In vivo imaging of DNA damage with [89Zr]Zr-DFO-anti-γH2AX-TAT following β-PRIT in a PDAC mouse model. A. Schematic representation of the β-PRIT and 
89Zr-PET imaging schedule in subcutaneous BxPC3 xenografted athymic nude mice. B. Representative transverse PET/CT images up to 4 days post-intravenous injection of 
[89Zr]Zr-DFO-anti-γH2AX-TAT (n=4 per cohort). Tumors are delineated with white dashed lines. C. Tumor VOI analysis of the PET/CT images up to 4 days p.i. (n=4 per 
cohort). D. Area under the curve of the tumor VOI analysis between 4 hours and 4 days p.i. (n=4 per cohort). E. Tumor uptake as determined through ex vivo gamma-counting 
post-animal sacrifice (n=5 per cohort). Values are represented as means, and error bars represent standard deviations. One-Way ANOVA followed by a Dunnett’s multiple 
comparisons test was applied. Adjusted P values: *** P ≤ 0.001, ** P≤ 0.01, * P≤ 0.05, n.s. = non significant. 
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Figure 3. In vivo imaging of DNA damage with [89Zr]Zr-DFO-anti-γH2AX-TAT following α-PRIT in a PDAC mouse model. Comparison with β-PRIT A. Representative 
transverse PET/CT images 24 hours post-intravenous injection of [89Zr]Zr-DFO-anti-γH2AX-TAT (n=4 per cohort). Tumors are delineated with white dashed lines. B. Tumor 
VOI analysis of the PET/CT images 24 hours p.i. (n=4 per cohort). C. Tumor uptake as determined through ex vivo gamma-counting post-animal sacrifice (n=5 per cohort). D. 
Comparison of the β-PRIT and α-PRIT DNA damage imaging cohorts in terms of [89Zr]Zr-DFO-anti-γH2AX-TAT tumor and muscle uptake as determined through ex vivo 
gamma-counting post-animal sacrifice (4 days and 24 hours post-administration of the PET radiotracer, respectively). Values are represented as means, and error bars represent 
standard deviations. One-Way ANOVA followed by a Dunnett’s multiple comparisons test was applied. Adjusted P values: ** P≤ 0.01, * P≤ 0.05, n.s. = non significant. 
 
Ex vivo γH2AX analysis correlates with in vivo 
89Zr-anti-γH2AX PET/CT imaging 
PET/CT results were confirmed via ex vivo 
immunohistochemistry and fluorescence staining of 
γH2AX foci in tumor sections following treatment 
with α-PRIT (37 kBq) and β-PRIT (18.5 MBq) (Figure 
4A, Figure S7). With immunohistochemistry, the 
percentage of cells staining positive for γH2AX 
expression was significantly higher (P < 0.0001) in the 
cohort treated with α- and β-PRIT as well as in the 10 
Gy positive control cohort (P < 0.01) when compared 
to the saline negative control cohort (Figure 4B). 
225Ac-PRIT treated tumors showed the highest 
percentage of γH2AX positive cells (66.9 ± 17.6 %) 
followed by the 177Lu-PRIT treated tumors (43.1 ± 15.7 
%), the 10 Gy cohort (26.4 ± 11.4 %), and finally the 
negative control (13.5 ± 5.51 %). Similarly, 
immunofluorescence γH2AX staining revealed 
increased fluorescence intensity and number of 
γH2AX foci per cell in the α-/β-PRIT treated cohorts 
(P < 0.0001). Notably, the detected number of γH2AX 
foci was twice as high in α-/β-PRIT cohorts (4.7 ± 1.0 
and 4.2 ± 1.4 foci/cell, respectively) as compared to 
the saline treated cohort (1.9 ± 0.9 foci/cell). 
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Figure 4. Ex vivo γH2AX immunostaining for the monitoring of α-/β-PRIT in tumor sections of PDAC mouse model 72 hours post-irradiation (n=3 per cohort). A. 
Representative microscopy images (orange scale = 200 μm, red scale = 50 μm). Zoomed-in area are provided in Supporting information (Figure S8) B. Percentage of γH2AX 
positive cells after immunohistochemistry analysis of tumor sections following α-/β-PRIT as compared to negative and positive controls (n=8 per slide). Quantification of: C. 
γH2AX fluorescent signal normalized to DAPI signal (n=8 per slide), and D. γH2AX foci per cell (n=6 per slide), after immunofluorescence analysis of tumor sections following 
α-/β-PRIT as compared to negative and positive controls. Values are represented as means, and error bars represent standard deviations. One-Way ANOVA followed by a 
Dunnett’s multiple comparisons test was applied. Adjusted P values: **** P≤ 0.0001, ** P≤ 0.01, n.s. = non significant. 
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Discussion 
There is presently no established non-invasive 
clinical approach for the local and systemic evaluation 
of radiation-induced biomarkers following targeted 
radionuclide therapy. Instead, targeted radionuclide 
therapies are not personalized to individual radiation 
response but rather administered at a set activity/kg 
based on observed general population response. 
When the field of targeted radionuclide therapy 
should transition to a personalized approach based on 
dosimetry, it is critical to develop in parallel 
non-invasive approaches for the evaluation of 
radiation-induced biomarker for early assessment and 
prediction of therapeutic response. Herein, we have 
demonstrated that 89Zr-PET imaging of DNA damage 
response is an effective non-invasive tool for the 
monitoring of the early therapeutic response 
following α- and β-particle molecular radiotherapy in 
a preclinical mouse model of PDAC.  
First, we validated that exposure to CA19.9 
targeted α- and β-particle molecular radiotherapy 
resulted in reduced viability and clonogenic survival 
in BxPC3 PDAC cells. Using the pretargeting 
administration method [5,6], we confirmed in vivo the 
higher therapeutic potential of the CA19.9 pretargeted 
α-particle radiotherapy as compared to β-particle 
radiotherapy, when administered in activity ratios 
that resulted in equitoxic effects in vitro. Such results 
are not surprising due to the higher RBE of α-particle 
and correlates with results previously reported with 
225Ac- and 177Lu-somatostatin receptor targeted 
radiotherapy [35]. However, they highlight the need 
for an in vivo predictor of radiation-induced effects, 
independent of the radiation type.  
PET imaging studies performed following 
β-particle PRIT in a BxPC3 PDAC subcutaneous 
xenograft mouse model allowed the establishment of 
an imaging protocol that enabled the monitoring of 
the tumor radiobiological response through γH2AX 
measurement. This non-invasive molecular imaging 
approach was successfully translated to α-particle 
PRIT. This study further highlights the versatile 
potential of the [89Zr]Zr-DFO-anti-γH2AX-TAT 
radiotracer for the imaging of response following the 
induction of DNA double-strand break damage from 
multiple sources (EBRT, α/β-particle) [25,29]. No 
evidence of a difference in 
[89Zr]Zr-DFO-anti-γH2AX-TAT uptake at the tumor 
site after α-PRIT and β-PRIT could be observed when 
α-PRIT resulted in prolonged survival compared to 
β-PRIT. This lack of evidence could be due to 
inter-experiment confounding factors but more 
importantly highlights that DNA damage is not the 
sole radiobiology paradigm and that off-targeted 
(bystander) effects should be considered when trying 
to compare different targeted radionuclide therapy 
approaches [36]. Our in vivo results were confirmed 
later with ex vivo γH2AX immunohistochemistry and 
immunofluorescence staining. Non-invasive 
therapeutic response assessment is critical at the 
preclinical stage to validate the potential of novel 
molecular radiotherapy approaches and expedite the 
clinical translation phase. In addition, such approach 
offers great clinical prospects as an in vivo 
biodosimeter for treatment response assessment at the 
molecular level to better tailor therapeutic regimens to 
patient response and elucidate the heterogeneous 
response observed between patients but also between 
different tumor sites or within the same tumor. The 
first clinical evaluation of this DNA damage 
radiotracer should investigate the correlation of early 
[89Zr]Zr-DFO-anti-γH2AX-TAT PET signal following 
targeted radionuclide therapy or EBRT to patient 
response evaluated at later time point according to the 
conventional RECIST/PERCIST criteria. Such 
evaluation should allow us to determine a γH2AX 
PET signal cut-off between responders and 
non-responders. 
A major limitation for the clinical translation and 
use of molecular radiotherapy approaches lies in the 
irradiation of healthy tissues following target 
engagement (on-target toxicity) or the non-specific 
accumulation of the radiopharmaceutical (off-target 
toxicity) [37,38]. γH2AX stands as a potential 
biomarker for radiation-induced toxicities and 
allowed previously the detection of 
radiotherapy-induced DNA damage in healthy 
human tissues, such as peripheral blood lymphocytes, 
hair follicles or kidneys [39–41]. Our DNA damage 
PET imaging should therefore allow the monitoring of 
on-/off-target toxicities. Our study did not allow such 
observation. Increased accumulation of our PET tracer 
in the blood and vascularized tissues was observed in 
the 177Lu-PRIT and first EBRT cohort, however this 
phenomenon was unlikely radiation-induced as it 
was not observed with the second EBRT cohort or 
with 225Ac-PRIT. Further preclinical studies should 
evaluate the potential of DNA damage PET imaging 
after targeted radionuclides therapies that 
demonstrate known toxicities to healthy tissues. 
In conclusion, we have demonstrated in a 
preclinical PDAC mouse model the potential of 
[89Zr]Zr-anti-γH2AX-TAT as an in vivo biodosimeter 
for α- and β-particle targeted radionuclide therapy 
response assessment. 
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